According to research performed by Diaceutics, utilizing data from its extensive laboratory network, the average post-launch delay in clinical uptake of a test is 4.5 years, within the biomarker-positive patient population it was meant to identify. Furthermore, based on this delay and inefficiencies related to lack of appropriate market development planning for CDx tests, 50% of patients within the oncology space alone will not have access to the right testing for the right biomarker-guided treatment.

In this case, they will help develop the CDx, gain regulatory approvals both in the US and ex-US, and help commercialize the assay by distributing it among their various lab partners.